Biogen (BIIB) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Biogen Revenue Highlights

Latest Revenue (Y)

$9.84B

Latest Revenue (Q)

$2.47B

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Biogen Revenue by Period

Biogen Revenue by Year

Date	Revenue	Change
2023-12-31	$9.84B	-3.32%
2022-12-31	$10.17B	-7.36%
2021-12-31	$10.98B	-18.32%
2020-12-31	$13.44B	-6.49%
2019-12-31	$14.38B	6.88%
2018-12-31	$13.45B	9.61%
2017-12-31	$12.27B	7.21%
2016-12-31	$11.45B	6.36%
2015-12-31	$10.76B	10.93%
2014-12-31	$9.70B	39.97%
2013-12-31	$6.93B	25.66%
2012-12-31	$5.52B	9.27%
2011-12-31	$5.05B	7.04%
2010-12-31	$4.72B	7.75%
2009-12-31	$4.38B	6.83%
2008-12-31	$4.10B	29.19%
2007-12-31	$3.17B	69.41%
2006-12-31	$1.87B	9.25%
2005-12-31	$1.71B	7.38%
2004-12-31	$1.60B	134.96%
2003-12-31	$679.18M	-40.86%
2002-12-31	$1.15B	10.06%
2001-12-31	$1.04B	12.62%
2000-12-31	$926.45M	16.62%
1999-12-31	$794.43M	42.48%
1998-12-31	$557.59M	28.46%
1997-12-31	$434.04M	56.64%
1996-12-31	$277.09M	82.67%
1995-12-31	$151.69M	-2.98%
1994-12-31	$156.34M	14.62%
1993-12-31	$136.40M	-

Biogen generated $9.84B in revenue during NA 2023, up -3.32% compared to the previous quarter, and up 73.11% compared to the same period a year ago.

Biogen Revenue by Quarter

Date	Revenue	Change
2024-09-30	$2.47B	4.79%
2024-06-30	$2.35B	6.94%
2024-03-31	$2.20B	-7.79%
2023-12-31	$2.39B	-5.69%
2023-09-30	$2.53B	3.03%
2023-06-30	$2.46B	-0.28%
2023-03-31	$2.46B	-3.18%
2022-12-31	$2.54B	1.42%
2022-09-30	$2.51B	-3.11%
2022-06-30	$2.59B	2.26%
2022-03-31	$2.53B	-7.39%
2021-12-31	$2.73B	-1.62%
2021-09-30	$2.78B	0.14%
2021-06-30	$2.77B	3.01%
2021-03-31	$2.69B	-5.56%
2020-12-31	$2.85B	-15.51%
2020-09-30	$3.38B	-8.30%
2020-06-30	$3.68B	4.17%
2020-03-31	$3.53B	-3.73%
2019-12-31	$3.67B	1.98%
2019-09-30	$3.60B	-0.46%
2019-06-30	$3.62B	3.64%
2019-03-31	$3.49B	-1.04%
2018-12-31	$3.53B	2.54%
2018-09-30	$3.44B	2.46%
2018-06-30	$3.36B	7.20%
2018-03-31	$3.13B	-5.32%
2017-12-31	$3.31B	7.45%
2017-09-30	$3.08B	-0.02%
2017-06-30	$3.08B	9.52%
2017-03-31	$2.81B	-2.13%
2016-12-31	$2.87B	-2.84%
2016-09-30	$2.96B	2.13%
2016-06-30	$2.89B	6.14%
2016-03-31	$2.73B	-3.96%
2015-12-31	$2.84B	2.21%
2015-09-30	$2.78B	7.19%
2015-06-30	$2.59B	1.44%
2015-03-31	$2.55B	-3.25%
2014-12-31	$2.64B	5.15%
2014-09-30	$2.51B	3.72%
2014-06-30	$2.42B	13.70%
2014-03-31	$2.13B	8.34%
2013-12-31	$1.97B	7.55%
2013-09-30	$1.83B	6.05%
2013-06-30	$1.72B	21.79%
2013-03-31	$1.42B	-37.80%
2012-12-31	$2.27B	107.23%
2012-09-30	$1.10B	-22.74%
2012-06-30	$1.42B	9.98%
2012-03-31	$1.29B	-2.62%
2011-12-31	$1.33B	1.28%
2011-09-30	$1.31B	8.38%
2011-06-30	$1.21B	0.44%
2011-03-31	$1.20B	-1.29%
2010-12-31	$1.22B	3.68%
2010-09-30	$1.18B	-3.04%
2010-06-30	$1.21B	9.36%
2010-03-31	$1.11B	-1.61%
2009-12-31	$1.13B	0.58%
2009-09-30	$1.12B	2.49%
2009-06-30	$1.09B	5.48%
2009-03-31	$1.04B	-3.03%
2008-12-31	$1.07B	-2.20%
2008-09-30	$1.09B	10.02%
2008-06-30	$993.44M	5.44%
2008-03-31	$942.19M	5.47%
2007-12-31	$893.30M	-

Biogen generated $2.47B in revenue during Q3 2024, up 4.79% compared to the previous quarter, and up 100.40% compared to the same period a year ago.

Biogen Revenue Breakdown

Biogen Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
TYSABRI product	$2.03B	-	-	-	-
Interferon	$1.31B	-	-	-	-
Fumarate	$2.00B	-	-	-	-
MS Product Revenues	$5.43B	-	-	-	-
Royalty	$67.40M	$27.90M	$33.90M	$17.00M	$38.70M
Product and Service, Other	$485.10M	$18.20M	$48.60M	$383.20M	-
Product	$7.99B	-	-	-	-
Revenues from anti-cd20 therapeutic programs	$1.70B	-	-	-	-
SPINRAZA	$1.79B	-	-	-	-
Other corporate revenues	-	$427.70M	$719.10M	$584.50M	$459.40M

Biogen's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product (35.04%), MS Product Revenues (23.82%), TYSABRI product (8.91%), Fumarate (8.76%), SPINRAZA (7.87%), Revenues from anti-cd20 therapeutic programs (7.46%), Interferon (5.73%), Product and Service, Other (2.13%), and Royalty (0.30%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
SPINRAZA	$381.40M	$429.10M	$341.30M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
TYSABRI product	$406.10M	$462.20M	$431.30M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
MS Product Revenues	$1.05B	$1.15B	$1.08B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interferon	$237.50M	$250.90M	$243.60M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fumarate	$390.90M	$418.00M	$381.80M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenues from anti-cd20 therapeutic programs	-	-	$394.00M	$433.40M	$399.50M	$447.90M	$416.90M	$436.30M	$399.40M	$414.10M	$415.40M	$440.00M	$389.00M	$419.00M	$560.10M	$478.30M	$520.40M	$600.80M	$595.80M	$576.40M
Product	-	-	$1.71B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product and Service, Other	-	-	$184.60M	$197.50M	$319.10M	$191.60M	$129.50M	$97.90M	$66.10M	$126.20M	$157.80M	$99.00M	$93.30M	$132.00M	$125.70M	$407.60M	$109.30M	$145.70M	$109.60M	$160.00M
Royalty	-	-	-	$14.40M	$12.20M	$8.80M	$10.30M	$7.60M	$7.70M	$6.40M	$6.20M	$5.10M	$10.30M	$7.10M	$11.40M	$7.10M	$3.30M	$2.70M	-	-
Other corporate revenues	-	-	-	-	-	-	$114.20M	$81.20M	$113.60M	$143.80M	$87.10M	$83.20M	$119.60M	$110.00M	$395.50M	$94.00M	$122.10M	$93.10M	$105.20M	-

Biogen's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: MS Product Revenues (42.67%), TYSABRI product (16.44%), Fumarate (15.83%), SPINRAZA (15.44%), and Interferon (9.62%).

Biogen Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
UNITED STATES	$3.47B	$1.14B	$1.10B	$5.50M	$1.02B
Asia	$672.10M	-	-	-	-
Europe	$2.40B	$100.00K	$200.00K	$200.00K	-
Segment Geographical Groups Of Countries Group Other	$64.00M	$61.80M	$80.30M	$78.30M	$76.60M
GERMANY	$926.20M	$1.16B	-	-	-
Europe, Excluding Germany	$100.00K	-	-	-	-
Non-US	-	$920.90M	$849.30M	$850.40M	$1.40M

Biogen's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (46.05%), Europe (31.88%), GERMANY (12.30%), Asia (8.92%), Segment Geographical Groups Of Countries Group Other (0.85%), and Europe, Excluding Germany (0.00%).

Quarterly Revenue by Country

Country	Sep 24	Jun 24	Mar 24	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Non-US	$956.40M	$1.05B	$965.80M	$15.90M	$14.70M	$12.50M	$9.90M	$6.90M	$236.30M	$224.70M	$241.70M	$224.40M	$230.00M	$204.40M	$212.30M	$187.90M	$244.70M	$203.40M	$220.60M	$211.00M
UNITED STATES	$813.00M	$846.70M	$746.10M	$130.30M	$93.50M	$138.30M	$127.90M	$129.90M	$284.50M	$288.00M	$281.10M	$299.80M	$273.30M	$270.80M	$304.20M	$244.10M	$277.70M	$269.50M	$263.00M	$264.30M

Biogen's latest quarterly revenue breakdown by geography, as of Sep 24: Non-US (54.05%), and UNITED STATES (45.95%).

Biogen Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
JNJ	Johnson & Johnson	$85.15B	$22.47B
MRK	Merck	$60.12B	$16.66B
PFE	Pfizer	$58.50B	$17.70B
ABBV	AbbVie	$54.32B	$14.46B
NVS	Novartis	$46.66B	$11.83B
BMY	Bristol-Myers Squibb Company	$45.01B	$11.89B
SNY	Sanofi	$43.07B	$11.12B
GSK	GSK	$30.33B	$7.36B
AMGN	Amgen	$28.19B	$8.50B
GILD	Gilead Sciences	$27.12B	$7.55B
BIIB	Biogen	$9.84B	$2.47B

BIIB Revenue FAQ

What is Biogen’s yearly revenue?

Biogen's yearly revenue for 2023 was $9.84B, representing a decrease of -3.32% compared to 2022. The company's yearly revenue for 2022 was $10.17B, representing a decrease of -7.36% compared to 2021. BIIB's yearly revenue for 2021 was $10.98B, representing a decrease of -18.32% compared to 2020.

What is Biogen’s quarterly revenue?

Biogen's quarterly revenue for Q3 2024 was $2.47B, a 4.79% increase from the previous quarter (Q2 2024), and a -2.55% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $2.35B, a 6.94% increase from the previous quarter (Q1 2024), and a -4.19% decrease year-over-year (Q2 2023). BIIB's quarterly revenue for Q1 2024 was $2.2B, a -7.79% decrease from the previous quarter (Q4 2023), and a -10.67% decrease year-over-year (Q1 2023).

What is Biogen’s revenue growth rate?

Biogen's revenue growth rate for the last 3 years (2021-2023) was -10.44%, and for the last 5 years (2019-2023) was -31.59%.

What are Biogen’s revenue streams?

Biogen's revenue streams in c 22 are TYSABRI product, Interferon, Fumarate, MS Product Revenues, Royalty, Product and Service, Other, Product, Revenues from anti-cd20 therapeutic programs, and SPINRAZA. TYSABRI product generated $2.03B in revenue, accounting 8.91% of the company's total revenue Interferon generated $1.31B in revenue, accounting 5.73% of the company's total revenue Fumarate generated $2B in revenue, accounting 8.76% of the company's total revenue MS Product Revenues generated $5.43B in revenue, accounting 23.82% of the company's total revenue Royalty generated $67.4M in revenue, accounting 0.30% of the company's total revenue, up 141.58% year-over-year. Product and Service, Other generated $485.1M in revenue, accounting 2.13% of the company's total revenue, up 2565.38% year-over-year. Product generated $7.99B in revenue, accounting 35.04% of the company's total revenue Revenues from anti-cd20 therapeutic programs generated $1.7B in revenue, accounting 7.46% of the company's total revenue SPINRAZA generated $1.79B in revenue, accounting 7.87% of the company's total revenue

What is Biogen’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Biogen was Product. This segment made a revenue of $7.99B, representing 35.04% of the company's total revenue.